RxDoctor Payments DataLook up a doctor →

Hunter Carrington, MD

Family Medicine · Hot Springs, ARNPI 1992016638

Payments from drug & device makers

$21,124in general payments, 2019–2025

Across 1,064 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$3K
  • Amgen$2K
  • GRT US Holding, Inc.$2K
  • GSK$1K
  • Otsuka America Pharmaceutical, Inc.$883
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$19,44999%
  • Education$1751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)200$2,951
AstraZeneca106$2,845
Amgen(2 entities)77$1,641
GRT US Holding, Inc.1$1,500
GSK62$1,015
Otsuka America Pharmaceutical, Inc.36$883
Pfizer72$714
Lilly USA, LLC56$683
Axsome Therapeutics, Inc.30$674
Johnson & Johnson23$665
Bayer25$497
Gilead18$465
Astellas Pharma US Inc16$430
Takeda Pharmaceuticals U.S.A., Inc.27$430
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)22$404
Boehringer Ingelheim15$339
Novo Nordisk18$335
Abbott17$326
Antares Pharma, Inc.16$318
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC17$288
Lundbeck LLC20$277
Supernus Pharmaceuticals, Inc.15$276
Biohaven Pharmaceuticals, Inc.9$215
Novartis16$213
Sunovion Pharmaceuticals Inc.20$207
Dexcom, Inc.11$192
Genentech USA, Inc.5$173
Teva Pharmaceuticals USA, Inc.11$171
Corium, LLC4$163
Procept Biorobotics Corporation1$156
Amarin Pharma, Inc.8$152
Vanda Pharmaceuticals Inc.7$123
Sanofi-aventis U.S. LLC2$116
Ironwood Pharmaceuticals, Inc7$98
Esperion Therapeutics, Inc.7$93
Kowa Pharmaceuticals America, Inc.7$92
Xeris Pharmaceuticals, Inc.5$88
Sumitomo Pharma America, Inc.6$85
Nestle Healthcare Nutrition Inc.5$81
Biohaven Pharmaceutical Holding Company Ltd.5$79
Halozyme Inc4$74
Merck4$60
Bausch Health US, LLC3$57
Pacira Therapeutics, Inc.2$55
Neurocrine Biosciences, Inc.2$46
Eisai Inc.3$45
Avanir Pharmaceuticals, Inc.3$45
Radius Health, Inc.2$39
Zyla Life Sciences, Inc.2$28
Redhill Biopharma Inc.2$27
Actelion Pharmaceuticals US, Inc.1$24
Arbor Pharmaceuticals, Inc.2$23
Sun Pharmaceutical Industries Inc.1$21
Biodelivery Sciences International, Inc.1$20
Verona Pharma, Inc.1$18
ARS Pharmaceuticals Operations, Inc.1$18
Shire North American Group Inc1$15
Bardy Diagnostics, Inc.1$15
Idorsia Pharmaceuticals US Inc1$15
Phathom Pharmaceuticals, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,124 in reported general payments places this provider in the 95th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$519,340
Medicare patients
959
Services billed
23,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide217$239,732
OzempicSemaglutide206$225,338
EliquisApixaban266$180,796
FarxigaDapagliflozin Propanediol148$136,853
Trelegy ElliptaFluticasone/Umeclidin/Vilanter124$117,362
IngrezzaValbenazine Tosylate12$109,921
TrulicityDulaglutide86$88,412
XareltoRivaroxaban96$82,455
JardianceEmpagliflozin87$82,356
LinzessLinaclotide65$60,902
XifaxanRifaximin14$57,818
NuplazidPimavanserin Tartrate23$56,889
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr78$54,344
EntrestoSacubitril/Valsartan65$44,002
SpravatoEsketamine Hcl12$43,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$683$328,143303 claims
Novo NordiskOzempic, Wegovy$335$253,070226 claims
PfizerEliquis, Nurtec Odt$714$198,703279 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,015$188,953237 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,845$147,219160 claims
Johnson & JohnsonXarelto, Spravato$665$126,112108 claims
Neurocrine Biosciences, Inc.Ingrezza$46$109,92112 claims
AbbVieLinzess, Vraylar$2,951$92,00785 claims
Boehringer IngelheimJardiance$339$82,35687 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$288$57,81814 claims
NovartisEntresto$213$44,00265 claims
MerckJanuvia$60$38,82731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →